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Summary  Hypothalamic-pituitary-adrenal  (HPA)-axis  dysregulation  is  a  prominent  ﬁnding
in more  severe  Major  Depressive  Disorder  (MDD),  and  is  characterized  by  increased  baseline
cortisol levels  at  awakening  (BCL),  blunted  cortisol  awakening  response  (CAR)  and  increased
area under  the  cortisol  curve  (AUC).  Selective  serotonin  reuptake  inhibitors  (SSRIs)  appear  to
normalize HPA-axis  dysfunction,  but  this  is  hardly  investigated  longitudinally.
We studied  salivary  BCL,  CAR  and  AUC  at  awakening  and  30  min  thereafter.  We  compared
measurements  in  initially  drug-free  MDD-patients  with  healthy  controls  (HCs)  at  study-entry.
In patients,  we  repeated  measures  after  6  and  12  weeks’  treatment  with  the  SSRI  paroxetine.
Non-responding  patients  received  a  randomized  dose-escalation  after  six  weeks’  treatment.We found  no  signiﬁcant  study-entry  differences  in  BLC,  CAR  or  AUC  between  MDD-patients
(n =  70)  and  controls  (n  =  51).  In  MDD-patients,  we  found  general  decreases  of  BCL  and  AUC
during paroxetine  treatment  (p  ≤  0.007),  especially  in  late  and  non-responders.  Importantly,
while overall  CAR  did  not  change  signiﬁcantly  over  time,  it  robustly  increased  over  12  weeks
especially  when  patients  achieved  remission  (p  ≤  0.041).  The  dose-escalation  intervention  did
not signiﬁcantly  inﬂuence  CAR  or  other  cortisol  parameters.
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In  conclusion,  paroxetine  seems  to  interfere  with  HPA-axis  dysregulation,  reﬂected  in  signiﬁcant
overall decreases  in  BCL  and  AUC  during  treatment.  Paroxetine  appears  to  decrease  HPA-axis
set-point  in  MDD,  which  might  result  in  increased  HPA-axis  activity  over  time,  which  is  further
improved  when  patients  achieve  remission  (ISRCTN  register  nr.  ISRCTN44111488).




























































































et  al.,  2009).  Following  approval  by  the  institutional  ethi-
cal  committee  and  written  informed-consent,  we  recruited
drug-free  outpatients.  Inclusion  criteria  were:  MDD  deter-. Introduction
he  hypothalamic-pituitary-adrenal-axis  (HPA-axis)  is  the
ain  endocrinological  regulator  of  allostasis.  A  robust  short-
erm  HPA-axis  response  to  acute  stress  may  confer  optimal
hysiological  function  and  reﬂect  adaptability  or  reactiv-
ty  to  environmental  demands  (Kudielka  et  al.,  2009;  Clow
t  al.,  2004).  However,  more  enduring  HPA-axis  hyperac-
ivity  is  seen  in  approximately  73%  of  patients  with  Major
epressive  Disorder  (MDD)  (Vreeburg  et  al.,  2009;  Holsboer,
000).  In  general  in  MDD,  HPA-axis  alterations  are  found  as  (I)
yperactivity:  increased  cortisol  in  blood  and  cerebrospinal
uid,  (II)  non-suppression:  higher  rates  of  non-suppression
o  the  dexamethasone  suppression  test  and  dexamethasone-
RH  (DEX-CRH)  test  (Heuser  et  al.,  1994;  Stetler  and  Miller,
011),  and/or  (III)  decreased  HPA-axis  feedback  inhibi-
ion.  These  factors  can  be  integrated  by  the  hypothesis
hat  impaired  glucocorticoid  receptor  (GR)-mediated  feed-
ack  inhibition  (non-suppression)  leads  to  a  higher  baseline
ortisol  secretion  (hyperactivity),  which  diminishes  reac-
ive  capacity  (Pariante,  2009).  These  HPA-disturbations  are
specially  observed  in  severe/melancholic  MDD  and/or  inpa-
ients  with  MDD  (Kunugi  et  al.,  2010;  Stetler  and  Miller,
011).  However,  decreased  HPA-axis  activity  was  also  found
Stetler  and  Miller,  2005;  Huber  et  al.,  2006),  in  particu-
ar  during  chronic  depressive  episodes  (duration  >2  years)
Kunugi  et  al.,  2010).  This  differential  stress-effect  might
xplain  contradictory  ﬁndings  of  HPA-axis  activity  in  MDD
tudies.
Selective  Serotonin  Reuptake  Inhibitors  (SSRIs)  are
ntidepressant  drugs  extensively  used  in  MDD.  Interest-
ngly,  besides  increasing  serotonergic  neurotransmission,
SRIs  might  also  change  HPA-axis  disturbances  (Vermetten
t  al.,  2006;  Aihara  et  al.,  2007).  Only  one  randomized
rial  has  been  performed  —  in  generalized  anxiety  disorder
 and  reported  reductions  in  HPA-axis  hyperactivity  dur-
ng  treatment  with  the  SSRI  escitalopram  versus  placebo
Lenze  et  al.,  2010).  Furthermore,  in  healthy  controls  (HCs),
PA-axis  awakening  response  signiﬁcantly  increased  after  six
ays  of  citalopram  versus  placebo  (Harmer  et  al.,  2003).  In
DD,  the  SSRI  ﬂuoxetine  decreased  corticotropin-releasing
ormone  (CRH)  (indicative  of  HPA-hyperactivity)  in  a  small
pen  study  (De  Bellis  et  al.,  1993).  A  16  weeks  open
tudy  with  citalopram  in  20  MDD-patients  showed  signiﬁ-
ant  decreases  in  cortisol  (after  DEX-CRH)  (Nikisch  et  al.,
005).  However,  after  5  weeks  of  treatment  with  the  SSRI
aroxetine  or  the  non-SSRI  amitriptyline,  HPA-axis  activity
nly  decreased  in  amitriptyline  responders  (Deuschle  et  al.,
003).Importantly,  effects  of  antidepressants,  including  SSRIs,
n  the  HPA-axis  seem  to  occur  mainly  in  MDD-patients
esponsive  to  treatment  (Deuschle  et  al.,  2003;  Nikisch




dPA-axis  abnormalities  resolve  as  a  result  of  SSRI  treatment,
r  due  to  clinical  improvement  (state  effect).  Nevertheless,
PA-axis  dysregulation  has  also  been  observed  in  remit-
ed  MDD  patients,  indicating  a  persistent  trait  (Bhagwagar
t  al.,  2003;  Lok  et  al.,  2011).  Therefore,  it  has  been  sug-
ested  that  resolving  HPA-axis  abnormalities  during  MDD
reatment  indicates  SSRI  response.  This  may  have  important
linical  implications,  also  explaining  why  persistent  HPA-axis
yperactivity  during  SSRI  treatment  predicts  MDD  relapse
Appelhof  et  al.,  2006;  Hardeveld  et  al.,  2014),  although
elapse  has  also  been  associated  with  HPA-hypoactivity
Bockting  et  al.,  2012).  These  HPA-axis  abnormalities  may
herefore  form  novel  targets  for  (add-on)  interventions
Pariante,  2009).  However,  to  date,  studies  longitudinally
nvestigating  the  HPA-axis  in  MDD-patients  during  SSRI  treat-
ent  to  disentangle  antidepressant  and  state  effects  are
argely  lacking,  especially  with  a  randomized  controlled  trial
esign.
To  investigate  (I)  HPA-axis  activity  and  awakening
esponse  in  MDD,  (II)  its  modulation  by  SSRIs,  and  (III)  its
ssociation  with  treatment  response,  we  repeatedly  mea-
ured  salivary  cortisol  responses  to  awakening  in  patients
reated  for  12  weeks  with  paroxetine.  First,  we  compared
atients  to  matched  HCs  at  study  entry.  Subsequently,  in  the
atients,  we  investigated  changes  in  HPA-axis  activity  over
ime  during  treatment.  Moreover,  we  included  a  random-
zed,  double-blind,  placebo-controlled  SSRI  dose-escalation
n  non-responders  after  six  weeks  of  treatment  (Ruhe  et  al.,
009),  enabling  investigation  of  causal  effects  of  differ-
nt  paroxetine  doses  on  HPA-axis  activity.  We  hypothesized
hat  (I)  MDD-patients  would  have  increased  HPA-axis  activ-
ty  and  decreased  awakening  response  compared  to  HCs;
II)  in  patients,  HPA-axis  dysregulation  would  improve  during
2  weeks  paroxetine-treatment;  (III)  this  change  would  be
specially  present  in  treatment  responders  (and  remitters),
nd  (IV)  effects  on  the  HPA-axis  would  be  more  outspoken
fter  dose-escalation  for  non-responders.
. Methods
.1.  Participants
his  study  reports  a  secondary  research  question  in  a  larger
tudy  (ISRCTN  register  nr.  ISRCTN44111488;  http://www.
rialregister.nl/trialreg/admin/rctview.asp?TC=193)  (Ruheined  by  the  structured  clinical  interview  for  DSM-IV  (SCID),
ge  18—70  years  and  a  Hamilton  Depression  Rating  Scale
core  (HDRS17-score)  >18.  All  participants  were  drug-naive  or




















































sLongitudinal  effects  of  the  SSRI  paroxetine  on  salivary  cortis
≤1  antidepressant  (other  than  paroxetine;  at  an  effective
dose  for  >4  weeks)  for  the  present  MDD-episode.
Exclusion  criteria  were:  bipolar  disorder,  psychotic  fea-
tures,  neurological  cognitive  impairments,  primary  anxiety
and/or  substance  abuse  disorders,  severe  suicidal  ideation
and  pregnancy.  We  allowed  (low  dose)  benzodiazepine  use,
and  excluded  patients  who  used  drugs  which  directly  affect
HPA-axis  activity  (e.g.  systemic  corticosteroids).
We  recruited  HCs  by  advertisements.  HCs  were  in  good
physical  health  and  never  used  psychotropic  medication.
Exclusion  criteria  for  HCs  were  SCID-positive  current  or
lifetime  psychiatric  disorder(s),  including  addiction  disor-
ders,  Beck  Depression  Inventory  score  >9,  >4  alcoholic
beverages/day  (last  month)  or  a  1st-degree  relative  with
psychiatric  disorder(s).  HCs  could  have  incidentally  used
illicit  drugs;  drug-use  one  month  prior  to  participation  was
not  allowed.
2.2.  Intervention
Patients  were  treated  at  the  outpatient  department  of  the
Program  for  Mood  disorders  of  the  Academic  Medical  Cen-
ter.  After  study-entry,  patients  were  treated  open  label
with  paroxetine  20  mg/day  for  6  weeks.  After  6  weeks
(T0),  responders  (≥50%  decrease  of  symptoms)  contin-
ued  treatment  with  paroxetine  20  mg/day  for  another  6
weeks  (T1).  Non-responders  were  randomized  at  T0  by  a
computer-program  and  received  either  a  true  paroxetine,  or
a  placebo  dose  escalation,  added  to  the  initial  dose  of  parox-
etine  20  mg/day  (Supplemental  Fig.  S1).  Dose-escalation
consisted  of  incremental  steps  of  one  capsule  every  5  days
(to  a  maximum  of  50  mg/day).  Paroxetine  serum  concentra-
tions  (PSC)  were  measured  at  T0  and  T1  with  a  validated
HPLC-MS/MS  method  (therapeutic  range  10—75  g/L).  For
more  details  see  Ruhe  et  al.  (2009).  Clinical  measurements
for  patients  were  scheduled  at  study-entry,  T0  and  T1.  HCs
were  measured  at  study-entry  only.
2.3.  HPA-axis
Several  studies  have  indicated  that  salivary  cortisol  lev-
els  are  valid  measures  of  HPA-axis  activity  (Westermann
et  al.,  2004;  Kirschbaum  and  Hellhammer,  1994;  Gallagher
et  al.,  2006;  Wust  et  al.,  2000),  particularly  the  physiologic
rise  in  cortisol  within  30  min  after  waking  up  (Clow  et  al.,
2004).  This  rise  has  been  hypothesized  to  be  able  to  quantify
both  HPA-activity  (cortisol  at  awakening;  baseline  cortisol
level;  BCL),  and  HPA-axis  feedback  inhibition  (difference
between  cortisol  30  min  after  awakening  and  awakening;
Cortisol  Awakening  Response;  CAR),  which  are  both  reﬂected
in  the  area  under  the  curve  (AUC).  These  measures  show
good  intra-individual  stability  across  time  and  can  quantify
subtle  changes  in  HPA-axis  regulation,  thereby  providing  a
valid  method  to  study  changes  in  HPA-axis  activity  over  a
treatment  period  (for  review  see  Fries  et  al.  (Fries  et  al.,
2009)).
After  instruction,  all  subjects  collected  salivary  sam-
ples  at  home,  immediately  after  awakening  and  30  min
thereafter.  Waking  time  and  the  time  of  the  second  saliva
sample  were  recorded.  Samples  were  refrigerated  and
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ontamination,  participants  refrained  from  brushing  their
eeth  or  eat  before  collecting  both  samples.  Cortisol
easurements  were  obtained  at  study-entry,  T0  and  T1,
nd  stored  at  −20 ◦C  until  analysis  by  radioimmunoassay
IBL  Hamburg;  designed  for  saliva  samples).  Intra-  and
nter-assay  variations  were  5.1%  and  6.5%,  respectively.
.4.  Statistics
.4.1.  Data  cleaning  and  missing  values
ll  cortisol-measures  were  normally  distributed.  As  done
reviously  (Vreeburg  et  al.,  2009),  we  considered  160%  of
he  highest  BCL  (41.4  nmol/L)  as  maximum  possible  CAR
alue  (70  nmol/L)  (Clow  et  al.,  2004).  Because  salivary  cor-
isol  levels  above  this  limit  are  likely  contaminated  by
lood  and  may  distort  further  analyses,  we  considered
/235  measurements  as  missing.  We  calculated  CAR  as  the
aliva  cortisol  level  measured  at  30  ±  10  min  after  awakening
inus  the  BCL.  Nineteen  measurements  outside  this  ±10  min
ange  were  also  considered  missing.  AUC  was  calculated
s  BCL  +  ½*CAR  (Fig.  S2).  In  order  to  quantify  how  missing
ata  inﬂuenced  results  we  also  performed  our  analyses  in
mputed  datasets,  which  is  explained  in  the  supplemental.
.4.2.  Treatment  response
e  operationalized  treatment  response  by  dividing  patients
nto  three  response  groups  based  on  HDRS17-score  rela-
ive  to  the  pre-treatment  score:  (I)  early  responders  (≥50%
ecrease  on  HDRS17-score  at  T0),  (II)  late  responders  (≥50%
ecrease  on  HDRS17-score  at  T1)  and  (III)  non-responders
<50%  decrease  on  HDRS17-score  at  T0 and  T1).  Remission
as  deﬁned  as  a  HDRS17 score  ≤7.
.4.3.  Analyses
e used  IBM-SPSS  v.19.0  for  all  analyses.  Clinical  data  were
nalyzed  on  intention  to  treat  (ITT)  basis  and  for  clinical
easures  of  drop-outs  we  used  a  last  observation  carried
orward  approach.  For  comparisons  of  patients  vs.  HCs,  we
sed  a  propensity  score  (PS1)  (Bartak  et  al.,  2009) represent-
ng  the  predicted  probability  for  a  case  to  belong  to  a  certain
roup,  calculated  in  a  binary  logistic  model  with  the  desired
onfounders  (including  age,  gender,  alcohol-use,  smoking
Kudielka  et  al.,  2009)  and  race  (Hajat  et  al.,  2010))  as  pre-
ictors  (Rosenbaum  and  Rubin,  1983).  For  comparison  of  the
hree  response  groups,  we  considered  age,  gender,  alcohol-
se,  smoking,  race,  and  body  mass  index  (BMI)  at  study-entry
s  covariates,  for  which  we  ﬁnally  included  only  variables
hat  differed  trendwise  (p  <  0.1)  univariately.  In  addition,
e  included  awakening  time  as  a  ﬁxed  covariate  in  all  anal-
ses  (Stalder  et  al.,  2009).  Because  non-responding  patients
t  T0 were  randomized  to  receive  a  dose-escalation  or  not,
onfounders  were  assumed  to  be  equally  distributed  (Table
1)  resolving  the  need  for  propensity  scores  for  analyses  of
ose-escalation.
For  comparisons  between  groups,  we  used  Linear  Regres-
ion  Analysis  with  BCL,  CAR  and  AUC  as  dependent
ariables  and  group  (patients  and  HCs,  ﬁnal  remitters  and
on-remitters,  dose-escalation)  as  independent  variable
including  the  propensity  score  and/or  covariates  as  indi-
ated).
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Referred for assessment of eligibility
(n= 278)
Sta rt open paroxet ine 20mg/d ay
(n= 70)
Randomizat ion of Non-responders open phase (n= 42)
Excluded before open phase
- In vited but withdrew (n= 27)
- Ineligible by crite ria (n= 88)
- Ineligible by current use of antidepressan ts (n= 37)
- Overall refusal to participate (n= 47)
- Excluded other reason s (n=9)
Dropout open phase paroxetine 20mg/day (n= 11)
- Inefficacy (n= 1)
- Adverse effects (n= 3)
- Other rea sons (n= 6)
- Withdrawn after interim (n= 1)
Responders (n= 17)
Paroxet ine do se-escalat ion (n= 21)
[paroxetine30-50mg/day]
Placebo dose-escalat ion (n= 21)
[paroxetine 20mg/day + placebo 10-30mg/day]
Paroxet ine continuation (n= 17)
[paroxetine 20mg/day]
Analyzable clinical data (n= 20)
- Wk 12 completer (n= 20)
Analyzable clinical data (n= 18)
- Wk 12 completer (n= 16)
Analyzable clinical data (n= 17)
- Wk 12 completer (n= 17)
Dropout Rand.  Pha se (n= 5)
- In efficacy (n= 3)
- Adverse effects (n= 3)
- Other reason s (n= 1)
Dropout Rand.  Pha se (n= 0)
- In efficacy (n= 0)
- Adverse effects (n= 0)
- Other reason s (n= 0)
Dropout Rand.  Pha se (n= 1)
- In efficacy (n= 0)
- Adverse effects (n= 0)





























































































did  not  signiﬁcantly  differ  for  other  variables  (all  p  >  0.12).,Figure  1  Pa
To  investigate  changes  in  cortisol  parameters  over  time
during  treatment)  in  all  patients  and  patient  subgroups,  we
sed  Linear  Mixed  Model  Analyses,  which  enable  to  mea-
ure  changes  of  parameters  over  time  and  the  interaction
ffects  of  subgroups*time  (Jaeger,  2008),  while  correcting
or  covariates.
In  the  mixed  models  investigating  treatment  response,
ortisol  parameters  were  the  dependent  variable  and
esponse  group  (early,  late  and  non-response),  follow-up
ime,  measurement  moment  and  their  interactions  were
ndependent  variables.  We  corrected  results  for  age,  gender
nd  for  variables  that  differed  between  the  three  response
roups  (p  <  0.1;  i.e.  alcohol  use  and  smoking)  and  awakening
ime  as  a  time-dependent  covariate.  Improvement  of  model-
t  was  judged  by  decreasing  Akaike  Information  criterion
AIC).
With  respect  to  quantiﬁcation  of  remission  effects,  two
odels  were  applied.  One  model  investigated  differences
etween  ‘ﬁnal  remitters  and  non-remitters’  as  a  group-
ariable  (i.e.  differences  between  effects  in  ﬁnal  remitters
nd  non-remitters  as  a  ﬁxed  variable  over  time),  while  the
econd  model  investigated  the  effect  of  ‘remission  as  a  time-
ependent  state-factor’  (i.e.  difference  between  subjects
n  remission  vs.  non-remitters  at  a  certain  time  point  during
reatment  which  is  changing  over  time).
. Results
.1.  Patient  disposition
eventy  patients  (mean  age  42.5  ±  7.8)  started  open  label
aroxetine  at  study-entry  (see  patient-ﬂow  in  Fig.  1).  At
0,  11  patients  had  dropped  out  before  week  6.  The  ITT
esponse  rate  in  the  open  phase  was  17/70  (24.3%);  so  42
on-responding  patients  were  randomized  at  T0 and  entered
he  double-blind  phase.  A  total  of  36  patients  completed





esponders  also  completed  another  6  weeks  of  treatment.
e  obtained  at  least  1  HDRS17 score  after  randomization  for
8  patients,  therefore  yielding  55  patients  for  the  longitu-
inal  analyses.  Of  these  55  patients  17  (30.9%)  were  early
esponders,  18  (32.7%)  were  late  responders  and  20  (36.4%)
ere  non-responders.  After  data-cleaning  we  obtained  63,
2  and  48  valid  cortisol  measurements  at  study-entry,  T0
nd  T1, respectively.  We  recruited  51  controls  of  whom
e  obtained  valid  cortisol  measurements  at  study-entry  for
7  subjects.  Subjects  without  valid  cortisol  measures  were
igniﬁcantly  younger,  and  of  non-Caucasian  heritage,  but
id  not  differ  on  other  demographic  characteristics,  or  (for
atients)  depression-related  characteristics  (data  available
n  request).
.2.  Population  characteristics
he  70  patients  had  a  mean  HDRS17 of  25.2  ±  4.4  (SD)  at
tudy  entry,  on  average  indicating  severe  MDD.  Fourteen
20%)  had  a  comorbid  (secondary)  anxiety  disorder  (eleven
anic  disorder/agoraphobia,  three  speciﬁc  phobia,  but  none
ad  a posttraumatic  stress  disorder  (PTSD)),  52  (74.3%)  had
elancholic  features,  31  (41.3%)  had  a  recurrent  MDE  and
 (12.9%)  had  a  MDE  for  >2  years.  Compared  to  controls,
atients  had  signiﬁcantly  lower  education-levels  and  were
ore  often  married  and/or  divorced  and  of  non-Caucasian
thnicity  (Table  1).  After  randomization  at  T0,  patient
roups  did  not  differ  signiﬁcantly  regarding  study-entry
haracteristics  (Table  S1).  With  regard  to  further  analyses,
arly  and  late  responders  smoked  and  drank  trendwise  more
han  non-responders  (p  ≥  0.06;  Table  S2).  Response  groupsinal  remitters  (n  =  15)  had  signiﬁcant  lower  study-entry
DRS17 scores  than  ﬁnal  non-remitters  (n  =  55;  22.4  ±  2.4
s.  26.0  ±  4.5;  p  =  0.004)  but  did  not  differ  otherwise  (data
vailable  on  request).
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Table  1  Characteristics  of  patients  and  healthy  controls.
MDD  patients  (n  =  70)  Healthy  controls  (n  =  51)  Signiﬁcancea
Age  (yrs  ±  SD)  at  study  entry  42.5  ±  7.8  42.4  ±  8.4  0.991
Sex
Female, n  (%)  46  (65.7)  33  (64.7)  1.000
Marital state,  n  (%)
Never  married  22  (31.4)  28  (54.9)  0.010
Married 25  (35.7)  15  (29.4)
Divorced 21  (30.0)  4  (7.8)
Widowed 1  (1.4)  1  (2.0)
Education,  n  (%)
Low  13  (18.8) 0  (0.0) <0.001
Intermediate  42  (60.9) 16  (31.4)
High 14  (20.3)  35  (68.6)
Alcohol use  (units/wk  ±  SD)  5.8  ±  10.7  6.9  ±  6.9  0.523
Current smoking  (cigarettes/day  ±  SD)  10.7  ±  12.4  6.9  ±  9.6  .079
Race, n  (%)
Caucasian  38  (54.3)  45  (88.2)  0.001
Creole 14  (20.0)  5  (9.8)
Asian 11  (15.7)  1  (2.0)
Other 7  (10.0)  0  (0.0)
MDE descriptives
HDRS17 (±  SD)  25.2  ±  4.4  N/A
Recurrent  MDD  (n(%))  30  (42.9)
Episode  >2  years  (n(%))  9  (13.0)
Melancholic  subtype  (n(%)) 52  (74.3)
Waking  up  time  (h  ±  SD)  07:22  ±  1:45  07:20  ±  1:27  0.912
Cortisolparameters b
BCL  (nmol/L  ±  SE)  12.9  ±  1.1  14.4  ±  1.3  0.388
CAR (nmol/L  ±  SE) 5.9  ±  1.2  6.3  ±  1.4  0.818
AUC (nmol/L  ±  SE) 16.2  ±  1.0 17.6  ±  1.2  0.399
Abbreviations:  AUC = area under the curve; BCL = baseline cortisol level; CAR = cortisol awakening response; HDRS17 = 17-item Hamilton
Depression Rating Scale; MDD = Major Depressive Disorder.
a /mixed models as appropriate.
ed on dataset without multiple imputation. See also Fig. S2.
3.4.1.  Association  with  treatment  response
As  a  next  step,  we  investigated  differences  in  changes  in
BCL,  CAR  and  AUC  over  time  between  the  three  responseDetermined by chi-square/independent samples t-test/ANOVA
b Corrected for propensity score and awakening time. Means bas
3.3.  Cortisol  parameters  at  study-entry
Although  mean  BCL,  CAR  and  AUC  were  numerically  lower  in
patients  compared  to  HCs,  these  differences  were  not  sig-
niﬁcant  at  study-entry  (all  p  >  0.24  uncorrected;  p  ≥  0.39)
corrected  for  PS1 and  awakening  time  (Table  1/Fig.  S2).
In  the  patient-group,  cortisol  parameters  at  study-entry
were  not  associated  with  HDRS-scores  (all  p  ≥  0.11;  Linear
Regression).  At  study  entry,  response  groups  did  not  differ
signiﬁcantly  with  respect  to  BCL,  CAR  or  AUC  at  study  entry
(p  >  0.103).  We  neither  observed  signiﬁcant  differences  in
study-entry  BCL,  CAR  and  AUC  between  ﬁnal  remitters  and
ﬁnal  non-remitters  (all  p  >  0.19;  corrected  for  HDRS17 at
study  entry  and  awakening  time).
3.4.  Changes  in  cortisol  parameters  over  time
during paroxetine  treatmentOn  average,  BCL  and  AUC  values  both  decreased  signiﬁcantly
over  time  (F1,50.703 =  8.090;  p  =  0.006  and  F1,51.921 =  7.756;
p  =  0.007,  respectively,  Fig.  2),  while  CAR  did  not  signiﬁ-
cantly  change  during  the  study  (F1,49.135 =  0.047;  p  =  0.830).
Figure  2  Changes  in  cortisol  parameters  over  time  (all
patients).
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measurements  of  treatment  with  paroxetine  in  the  MDD-esponse  groups.
roups  in  a  mixed  model,  by  testing  response-group*time
nteractions  (correcting  for  alcohol  use,  smoking  and  awak-
ning  time).  Because  by  design  late  and  non-responding
atients  received  different  dosages  of  paroxetine  after  T0
randomization  of  only  non-responders),  we  added  PSCs
s  additional  time-dependent  covariate,  which  improved
he  models  (based  on  lower  AIC).  We  found  signiﬁ-
ant  response*time  interactions  for  AUC  (F2,42.433 =  3.976; =  0.026)  and  a  trendwise  interaction  for  and  BCL
F2,42.832 =  2.335;  p  =  0.11),  but  not  for  CAR  (F2,44.753 =  0.201;
 =  0.819,  Fig.  3).  In  late  and  non-responders  we  observed  a
p
o
mFigure  4  CAR  in  ﬁnal  remitters  vs  non-remitters.
ecrease  in  AUC  while  in  early  responders  the  AUC  slightly
ncreased  over  12  weeks  of  treatment.
.4.2.  Association  with  remission  of  the  depressive
pisode
or  ﬁnal  remitters  and  non-remitters,  changes  in  CAR  over
ime  differed  signiﬁcantly,  despite  comparable  CAR-values
t  study-entry.  Final  remitters  showed  a  signiﬁcant  increase
n  CAR,  while  CAR  in  ﬁnal  non-remitters  did  not  change
ﬁnal-remission*time  interaction  F1,52.571 =  4.400;  p  =  0.041;
ig.  4).  Although  by  itself  PSCs  were  not  signiﬁcantly  asso-
iated  with  CAR  (F1,62.130 =  0.031;  p  =  0.860),  adding  this
ariable  contributed  signiﬁcantly  to  this  model,(decreasing
he  AIC).  AUC  and  BCL  did  not  differentially  change  over
ime  for  ﬁnal  remitters  versus  non-remitters  (all  p  >  0.37).
Additionally,  to  investigate  whether  remission  status
either  at  T0  or  T1)  was  associated  with  higher  CARs,  we
ncluded  remission  as  a  time-dependent  variable  in  the
inear  Mixed  Model  Analyses.  Indeed,  this  showed  that
emission,  at  any  time-point,  was  associated  with  higher
ARs  (F1,80.519 =  5.682;  p  =  0.019).  This  association  did  not
hange  over  time  as  the  remission  status*time  interaction
as  not  signiﬁcant  (p  =  0.673).
.5.  True  paroxetine  versus  placebo
ose-escalation  after  randomization
fter  randomization  groups  did  not  differ  signiﬁcantly  for
DRS17 or  cortisol  measures  at  T0  (all  p  >  0.18;  data  avail-
ble  on  request).  Remission  rates  were  3  (14.3%)  in  the  true
nd  2  (9.5%)  in  the  placebo-dose-escalation  groups  (p  =  1.000
isher’s  Exact).  Dose-escalation  after  6  weeks  of  treatment
id  not  signiﬁcantly  affect  BCL,  AUC  or  CAR-courses  (condi-
ion*time  interaction;  all  p  >  0.08;  Table  2).
. Discussion
his  study  investigated  differences  in  salivary  cortisol
etween  HCs  and  MDD-patients  and  the  effects  on  cortisolatients.  We  found  no  signiﬁcant  differences  in  BCL,  CAR
r  AUC  between  controls  and  MDD-patients.  Before  treat-
ent,  BCL,  CAR  and  AUC  at  study-entry  were  also  similar
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Table  2  Changes  in  cortisol  parameters  for  placebo-  and  true  dose-escalation  groups.
Placebo  dose-escalation  True  dose-escalation
T0 T1 T0 T1
AUC  nmol/L  12.4  ±  1.5  11.7  ±  1.6  13.2  ±  1.3  11.3  ±  1.6
BCL nmol/L  8.9  ±  1.3  9.6  ±  1.5  10.3  ±  1.2  7.5  ±  1.5
CAR nmol/L  7.1  ±  1.8  2.6  ±  1.8  5.7  ±  1.6  6.7  ±  1.7
Between T0 (randomization to dose escalation) and T1 we found no signiﬁcant differences in changes in cortisolparameters (mean ± SE)
between patients who received placebo dose-escalation versus patients who received real dose-escalation (p > 0.08; Linear Mixed Model









































dMeans based on dataset without multiple imputation.
AUC = area under the curve, BCL = baseline cortisol level, CAR = co
in  (early/late)  ﬁnal  responders  versus  non-responders  and
in  ﬁnal  remitters  and  non-remitters.  More  speciﬁcally,  after
paroxetine-treatment,  we  observed  a  decrease  of  BCL  and
AUC  in  MDD-patients  over  time.  Especially  in  early  respon-
ders  the  AUC  increased  over  time,  and  interestingly,  robust
increases  in  CAR  were  found  in  patients  who  achieved  remis-
sion  from  MDE  while  no  increases  in  AUC  or  CAR,  were
observed  in  late/non-responders  and  non-remitters,  respec-
tively.  Furthermore,  remission  status  during  treatment  was
signiﬁcantly  associated  with  higher  CARs.  The  randomized
dose-escalation  in  42  non-responders  6  weeks  after  study-
entry  did  not  signiﬁcantly  inﬂuence  BCL,  AUC  or  CAR.
4.1.  Cortisol  parameters  at  study-entry
4.1.1.  Hyperactivity
Our  hypothesis  of  HPA-axis  hyperactivity  in  MDD-patients
compared  to  controls  had  to  be  rejected.  Moreover,  our
numerical  results  even  indicate  lower  HPA-axis  activ-
ity.  However,  given  the  small  differences,  our  study  was
clearly  underpowered  (power  =  0.12  for  a  double-sided
test  at  ˛  =  0.05)  to  signiﬁcantly  detect  these  differences
relative  to  HCs  at  study-entry  (Fig.  S2).  Previous  stud-
ies  comparing  MDD-patients  and  HCs  concerning  cortisol
parameters  showed  inconsistent  results,  although  a  recent
meta-analysis  of  361  studies  in  18,454  individuals  reported
HPA-axis  hyperactivity  with  small  effect  sizes  in  outpatient
populations  with  MDD  (Stetler  and  Miller,  2011).
4.1.2.  Awakening  response
Although  the  CAR  was  indeed  numerically  lower  in  our
patient  group,  we  could  not  conﬁrm  our  hypothesis  of
decreased  HPA-axis  awakening  response  in  patients  versus
controls.  Evidence  exists  for  a  blunted  CAR  in  MDD  (Stetler
and  Miller,  2005;  Huber  et  al.,  2006)  and  Seasonal  Affec-
tive  Disorder  (SAD)  during  winter  (Thorn  et  al.,  2011)
which  might  be  associated  with  a  change  in  diurnal  sleep-
wake  rhythm  or  lack  of  social  contacts  (Stetler  and  Miller,
2005).  However,  also  higher  CARs  (Pruessner  et  al.,  2003;
Bhagwagar  et  al.,  2005;  Vreeburg  et  al.,  2009)  were  reported
in  MDD-patients  compared  to  HCs.4.1.3.  Explaining  inconsistencies
Some  explanations  for  these  inconsistencies  should  be  con-
sidered.  First,  previous  studies  show  larger  effects  in  more





ince  we  also  selected  an  average  severe  group  (mean
DRS17 =  25.2),  this  does  not  seem  plausible.  Second,  differ-
nt  subpopulations  and  (omission  of)  correction  for  different
onfounding  variables  (Vreeburg  et  al.,  2009) may  provide
lariﬁcation.  Indeed,  different  disease  duration,  comorbid-
ty,  depression  severity  and  subtypes  of  MDD  affect  ﬁndings
n  HPA-axis  abnormalities  (Kunugi  et  al.,  2010;  Shelton,
007;  Lamers  et  al.,  2013).  Atypical  depression  and  SAD
esult  in  HPA-axis  hypoactivation  (Thorn  et  al.,  2011),  in
ontrast  to  melancholic  depression  being  characterized  by
PA-axis  hyperactivation  (Kunugi  et  al.,  2010;  Lamers  et  al.,
013),  but  this  is  equivocal  (Stetler  and  Miller,  2011).  Higher
ARs  were  especially  found  in  association  with,  more  severe
nhedonia  (Wardenaar  et  al.,  2011),  which  was  replicated
y  Veen  et  al.  (2011)  reporting  signiﬁcant  correlations
etween  CAR  and  general  distress  symptoms.  Therefore,
orrection  for  differences  in  depression  duration  or  subtype,
nhedonia  and  general  distress  should  ideally  be  applied,
ut  are  statistically  not  meaningful  (and  even  inappropri-
te)  in  relatively  small  samples  like  ours.  Nevertheless,
n  our  moderate  to  severely  ill,  predominantly  melan-
holic  (>74%  of  the  patients  were  melancholic)  depressed
atients  without  comorbid  diseases  like  PTSD,  these  factors
nlikely  will  explain  our  results.  Although  —  indeed  —  mean
AR  at  study-entry  was  numerically  lower  in  chronic  MDD-
atients  (0.60  ±  3.56  nmol/l  [SE];  n  =  9)  versus  non-chronic
6.14  ±  1.21  nmol/l)  MDD-patients,  these  differences  in  BCL,
AR  or  AUC  were  not  signiﬁcant  (p  =  0.61;  p  =  0.18;  p  =  0.73,
espectively;  post  hoc).  Therefore,  in  our  MDD-sample  it
emains  speculative  why  we  found  non-signiﬁcantly  lower
CL-  and  CAR-levels  at  study  entry.  Instead  of  HPA-axis
yperactivity,  these  observations  might  indicate  blunted
PA-axis  activity  and  diminished  awakening  response
Stetler  and  Miller,  2005;  Huber  et  al.,  2006;  Chida  and
teptoe,  2009),  which  improved  after  remission  (see  below).
.2.  Changes  in  cortisol  parameters  during
reatment  and  association  with  treatment  response
ne  robust  ﬁnding  is  the  signiﬁcant  decrease  in  BCL  (and
UC)  during  treatment,  suggesting  that  SSRI  treatment
ecreases  the  cortisol  ‘setpoint’  (Holsboer,  2000;  Schule,
007).  Previous  studies  also  reported  a  decreasing  effect  of
SRIs  on  HPA-axis  hyperactivity  (Nikisch  et  al.,  2005;  Buhl
t  al.,  2010;  Lenze  et  al.,  2010),  although  contradictory

















































































































n  theory,  lowering  the  cortisol  setpoint  could  facilitate
mprovement  of  HPA-axis  awakening  response  which  was
uggested  to  be  blunted  in  MDD  (Pariante,  2009).
While  other  studies  predominantly  reported  effects  on
CL  only  in  treatment  responders  (Nikisch  et  al.,  2005;
euschle  et  al.,  2003),  we  observed  decreases  in  AUC  espe-
ially  in  late  and  non-responders,  which  was  signiﬁcant  for
he  AUC  and  showed  a  trend  for  BCL.  Furthermore,  at  all
easurements  over  the  treatment  period,  CAR  was  numer-
cally  higher  in  the  early  response  group  (n.s.;  Fig.  3).
ecause  the  AUC  represents  a  combined  measure  for  BCL
nd  CAR,  these  data  together  are  suggestive  of  an  increase
n  CAR  without  changes  in  BCL  in  early  responders  and
 decrease  in  BCL  and  no  change  in  CAR  in  late  and
on-responders.  Since  groups  did  not  differ  signiﬁcantly
n  study-entry  HDRS17-scores,  other  MDD-characteristics
duration  of  current  episode,  melancholic  features)  and  HPA-
easures,  it  remains  elusive  what  differentiates  late  and
on-responders  from  early  responders  and/or  whether  the
ate/non-responders  are  more  severely  disturbed  (Fig.  3  and
able  S2).
Importantly,  we  found  that  especially  achieving  remission
as  associated  with  increases  in  CAR  during  paroxetine-
reatment.  This  corroborates  ﬁndings  that  in  a  large  sample,
igniﬁcantly  higher  CARs  were  found  in  remitted  patients
elative  to  controls  (Vreeburg  et  al.,  2009)  which  was  also
ound  in  drug-free  remitted  patients  (Aubry  et  al.,  2010).
ost  hoc,  in  our  sample  ﬁfteen  remitters  had  higher  CARs  at
ndpoint  than  controls  at  study-entry  (11.1  ±  2.5  nmol/l  [SE]
ersus  6.2  ±  1.3  nmol/l  [SE],  respectively  (p  =  0.08)).  CAR
ncreases  could  be  interpreted  as  a  return  of  normal  HPA-axis
ctivity  (Kudielka  et  al.,  2009;  Clow  et  al.,  2004;  Pariante,
009).  A  decrease  in  BCL  might  in  fact  increase  the  range
f  the  awakening  response,  as  reported  before  (Holsboer,
000;  Buhl  et  al.,  2010;  Lenze  et  al.,  2010;  Schule,  2007).
ndeed,  when  we  post  hoc  associated  (repeated)  measures
f  CAR  with  BCL,  we  found  a  signiﬁcant  inverse  associa-
ion  between  BCL  and  CAR,  which,  in  addition,  became
tronger  over  time  (BCL*time  interaction  F1,91.707 =  4.388;
 =  0.039),  while  remission-status  at  T0 or  T1 remained  a
igniﬁcant  independent  predictor  for  CAR  (F1,82.130 =  4.639;
 =  0.034;  all  corrected  for  awakening  time).  These  results
uggest  that  paroxetine  treatment  improves  HPA-awakening
esponse  (CAR)  by  a  stronger  inverse  association  with  BCL
ver  time  of  treatment  (when  BCL  decreases),  where  in
ddition  occurrence  of  remission  further  improves  HPA-axis
esponsiveness.
Increases  in  CAR  as  a  representation  of  restored  HPA-axis
ctivity  seems  at  odds  with  associations  of  higher  CAR  with
isks  for  MDD.  Furthermore,  CAR  was  also  increased  in  indi-
iduals  with  a  parental  history  of  MDD  (Vreeburg  et  al.,  2010)
nd  in  people  with  SAD  (Thorn  et  al.,  2011).  In  a  prospective
tudy,  young  adults  with  higher  CARs  had  signiﬁcant  more
isk  to  develop  a  depressive  episode  during  one  (Adam  et  al.,
010)  and  2.5-year  follow-up  (Vrshek-Schallhorn  et  al.,
013).  We  previously  showed  that  increased  HPA-axis  activ-
ty  (at  8:00  and  22:00  h)  exists  in  highly  recurrent  but  remit-
ed  MDD-patients  (Lok  et  al.,  2011).  In  a  large  population
ased  study,  higher  CARs  predicted  recurrence  (Hardeveld
t  al.,  2014).  These  ﬁndings  could  be  interpreted  as  that  high
ARs  also  represent  a  trait  marker  for  MDD-vulnerability  or
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ssociated  with  improved  cognition  (Law  et  al.,  2013;  Evans
t  al.,  2011).  Higher  CARs  might  thus  represent  an  adap-
ive  phenomenon:  as  a  ‘preparation  of  the  day’  to  increase
ognitive  compensation  (e.g.  for  daily  hassles)  and  improve
xecutive  functioning  in  patients  with  (recurrent)  MDD  even
hen  in  remission.  If  this  adaptive  phenomenon  collapses
e.g.  after  exhaustion  and  decreased/blunted  CARs),  a
new)  depressive  episode  might  occur,  which  is  corroborated
y  the  ﬁnding  that  especially  HPA-hypoactivity  was  associ-
ted  with  relapse  (Bockting  et  al.,  2012).
In  the  present  study  we  additionally  investigated  the
ose—response  relationship  of  paroxetine  with  respect  to
hanges  in  HPA-axis  disfunction.  However,  the  second  phase
f  six  weeks  true  paroxetine  versus  placebo  dose-escalation
evealed  no  signiﬁcant  differences  in  BCL,  AUC  or  CAR
etween  dose-groups.  This  null-ﬁnding  corroborates  with
revious  observations  that  dose-escalation  of  paroxetine
and  other  SSRIs)  does  not  improve  symptomatology  (Ruhe
t  al.,  2006;  Adli  et  al.,  2005)  and  neither  increases  SERT-
ccupancy  (Ruhe  et  al.,  2009).
An  explanation  for  the  changes  in  cortisol  measures
uring  treatment  with  paroxetine  and  the  absence  of  asso-
iations  with  PSC  or  paroxetine  dose,  might  lie  in  the
on-serotonergic  SSRI-effects  on  HPA-axis  activity.  Acute
dministration  of  antidepressants  causes  increases  in  GR
xpression  and  function,  but  after  chronic  treatment  of
odents,  GR-expression  returns  to  control  levels,  while  basal
PA-axis  activity  is  still  reduced.  Currently,  changes  in
PA-axis  activity  after  chronic  treatment  with  SSRIs  are
hought  to  inhibit  the  multidrug  resistance  P-glycoprotein.
his  P-glycoprotein  also  expels  glucocorticoids  from  cells,
o  SSRIs  might  indirectly  increase  intracellular  concentra-
ions  of  glucocorticoids,  which  can  improve  GR-function
ith  increased  awakening  response  as  a  result.  It  is  of  inter-
st  that  this  P-glycoprotein  inhibition  might  not  occur  in
reatment  resistant  patients  (Pariante,  2009).  Especially  the
on-responders  and/or  non-remitters  in  this  study  might
ave  been  early  refractory  patients,  who  might  not  have
chieved  ﬁnal  remission  after  several  successive  treatment-
teps  (Ruhe  et  al.,  2012).  Unfortunately  these  patients  were
ot  followed  up  routinely  to  conﬁrm  this.
.3.  Limitations  and  strengths
ost  importantly,  paroxetine  treatment  was  not  fully
lacebo-controlled,  and  only  patients  were  followed-up.
easuring  controls  during  the  same  follow-up  would  have
uantiﬁed  effects  of  repeated  sampling.  A  full  placebo  group
ould  have  differentiated  true  drug  effects  from  nonspe-
iﬁc  effects  of  remission  and/or  over  time.  Full  placebo
reatment  was  not  pursued  because  of  ethical  reasons  and
he  original  aim  of  the  study  (efﬁcacy  of  dose-escalation).
evertheless,  the  placebo-controlled  dose-escalation  phase
f  this  study  did  not  identify  dose-related  drug-effects
n  HPA-axis  parameters.  Second,  although  we  corrected
or  awakening-time  and  age,  gender,  alcohol-use,  smoking,
ace,  BMI,  HDRS17-scores  at  study-entry  in  the  propensity-
cores,  we  did  not  have  data  to  control  for  potential  other
onfounders  like  menstrual  cyclus,  late  evening/night  work-
ng  hours  or  childhood  adversity.  Neither  did  we  instruct
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was  however  mostly  done  the  day  before  baseline  visits  dur-
ing  the  week),  nor  did  we  quantify  or  speciﬁcally  restrict
alcohol  use  the  night  before  sampling.  Third,  a more
advanced  HPA-axis  sampling  protocol  would  have  enabled  us
to  additionally  detect  more  subtle  changes.  We  only  sampled
at  one  day  during  the  week,  while  nowadays  it  is  considered
good  practice  to  base  assessment  upon  measures  repeated
on  two  consecutive  weekdays.  This  could  have  provided
some  measure  of  trait  stability.  We  neither  obtained  saliva
samples  at  15,  45  and  60  min  after  awakening,  nor  a  diurnal
proﬁle  beyond  these  timepoints,  which  would  have  enabled
us  to  determine  more  complete  parameters  of  the  corti-
sol  awakening  curve.  Especially  45  min  post  waking  samples
are  important  for  females  who  peak  later  than  males.  Our
restriction  to  obtain  two  cortisol  measurements  only,  might
also  have  obscured  a  difference  between  patients  and  con-
trols.  We  did  not  use  objective  electronic  monitoring  or  an
actimeter  to  reduce  uncertainty  of  the  actual  wake  and
saliva  sampling  times.  However,  despite  these  limitations,
our  methods  resulted  in  interesting  changes  in  repeated
cortisol  measures  that  were  longitudinally  associated  with
clinical  course  of  depressive  symptoms.  Fourth,  we  did
not  differentiate  other  sub-types  than  melancholic/atypical
depression.  Differentiation  of  other  symptom-axes  in  MDD
might  better  corresponds  with  particular  HPA-axis  dysregu-
lation  (Veen  et  al.,  2011;  Wardenaar  et  al.,  2011).  In  future
studies  sub-types  should  differentiated  with  the  Mood  and
Anxiety  Symptoms  Questionnaire  (Wardenaar  et  al.,  2011).
Fifth,  this  type  of  research  is  susceptible  to  confounding
by  missing  data,  which  also  occurred  in  our  sample.  How-
ever,  the  main  results  of  this  study  remained  the  same
when  we  performed  multiple  imputation  (see  supplemen-
tal).  Sixth,  the  slight  different  deﬁnitions  of  BCL-  and
CAR-measurements  between  studies  complicate  the  discus-
sion  of  comparisons  between  studies.  This  urges  for  uniform
nomenclature  and  standardization  of  HPA-axis  measures.
Major  strengths  of  our  study  are  that  (I)  we  investigated
the  longitudinal  effects  of  SSRI  treatment  on  HPA-axis  activ-
ity,  (II)  in  patients  drug-free  at  study-entry  and  (III)  treated
uniformly  according  to  a  study  protocol,  and  (IV)  our  results
appeared  robust  when  applying  MI  to  resolve  potential  bias
by  missing  values  (drop-outs  and  outliers).  Altogether,  these
strengths  allowed  us  to  longitudinally  disentangle  antide-
pressant  and  state  effects  on  HPA-axis  activity  in  MDD.
5. Conclusion
This  study  investigated  changes  in  salivary  cortisol  over  time
during  treatment  with  paroxetine  and  a  randomized  dose-
escalation.  Without  evidence  for  baseline  differences  com-
pared  to  controls,  we  found  signiﬁcant  decreases  in  BCL  and
AUC  in  all  patients  over  12  weeks  of  paroxetine  treatment,
suggesting  that  SSRIs  decrease  HPA-axis  set-point  in  MDD,
which  was  most  prominent  in  late  and  non-responders,  while
early  responders  showed  no  change.  The  robust  CAR  increase
especially  when  patients  became  remitters  versus  no  change
in  non-remitters  during  paroxetine  treatment,  suggests  that
improved  HPA-axis  feedback  inhibition  may  result  from  a
combination  of  overall  decreasing  cortisol  values  due  to  SSRI
treatment  and  additional  increased  activity  of  the  HPA-axis
when  patients  remit  from  a  depressive  episode.
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